A GCC nephrology network capacity survey estimates 8,000-12,000 total IgA nephropathy patients, but fewer than 30% of eligible proteinuric cases are ever biopsied, and zero patients are on any SFDA-registered novel agent, a gap this model sizes explicitly rather than fabricating a biopsy-confirmed count.
Two methods size the GCC IgA nephropathy population, and, as with every AXLRx GCC rare disease model, they are triangulated rather than averaged. The capacity-survey method starts from a GCC nephrology network capacity survey, which puts total regional IgAN prevalence at 8,000 to 12,000 patients. This is a modeled estimate rather than a registry count, because no GCC state maintains a national registry specific to IgA nephropathy, unlike the UK Renal Registry or the claims-based counts available in the US market.
The second method is diagnostic-yield-based: KDIGO guidance calls for kidney biopsy in non-diabetic proteinuria, yet the same nephrology network capacity survey finds GCC practice performing biopsy in fewer than 30% of eligible proteinuric patients, against roughly 70% in Japan and Germany, with biopsy capability concentrated at fewer than 20 GCC centres. That leaves a hard biopsy-confirmed patient count as a genuine open data gap for the region, one this model states explicitly rather than estimating. As of 2024, neither budesonide (Tarpeyo) nor sparsentan (Filspari) is SFDA-registered anywhere in the GCC, so the on-novel-therapy count is zero. This model states that zero directly rather than inferring a penetration rate from US or European data, consistent with the AXLRx GCC IgA Nephropathy Patient Flow Model's treatment-reality gate.
GCC IgA nephropathy sizing — capacity-survey versus biopsy-rate triangulation
| Sizing Method | Population Estimate | Source |
|---|---|---|
| Capacity-survey-based (total estimate) | 8,000–12,000 total GCC IgAN patients | GCC nephrology network capacity survey 2022 |
| Diagnostic-yield-based (biopsy rate) | Fewer than 30% of eligible patients biopsied (vs ~70% Japan/Germany) | GCC nephrology network capacity survey 2022; KDIGO 2021 IgAN guideline |
| Biopsy-confirmed count | Not yet available; flagged as an open data gap, not estimated | AXLRx GCC IgA Nephropathy Patient Flow Model |
| On novel therapy today | 0 (no SFDA-registered novel IgAN agent as of 2024) | SFDA drug registration database query 2024 |
Sources: GCC nephrology network capacity survey 2022; KDIGO 2021 IgA nephropathy guideline; SFDA drug registration database query 2024; Gulf renal registry 2022.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- GCC nephrology network capacity survey methodology
- the fewer-than-30% biopsy-rate diagnostic gate versus roughly 70% in Japan and Germany
- why AXLRx flags the biopsy-confirmed count as an open data gap rather than estimating one
Delivers
- SFDA registration status for budesonide (Tarpeyo) and sparsentan (Filspari) as of 2024
- the honest-zero methodology
- the pre-launch forecasting implication for GCC sizing work
Delivers
- Sensitivity ranking across every input
- scenario ranges tied to biopsy-capacity expansion across the fewer-than-20-centre network
- the assumption most likely to move planning numbers under an internal challenge
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why the kidney-biopsy capacity constraint, not the prevalence estimate, decides how much of the true GCC IgAN population is ever counted
- Pressure-tested against the capacity-survey-vs-biopsy-rate gap before the rest of the model is built out
- The GCC nephrology network capacity survey behind the 8,000-12,000-patient total
- Why no GCC state maintains a national registry specific to IgA nephropathy
- The kidney-biopsy rate of fewer than 30% among eligible proteinuric patients, versus roughly 70% in Japan and Germany
- Why a hard biopsy-confirmed patient count remains an open data gap for the GCC
- Where the capacity-survey estimate and the biopsy-rate evidence agree and diverge
- The fewer-than-20-centre biopsy-capacity constraint as the explanation for the gap
- SFDA registration status for budesonide (Tarpeyo) and sparsentan (Filspari) as of 2024
- Why this model states an honest zero rather than borrowing a penetration rate from the US or Europe
- Ranking the prevalence estimate, biopsy rate, and SFDA registration timing by impact on the total
- Scenario ranges tied to biopsy-capacity expansion
- The open sizing questions your team must close before the number is used in planning
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx market sizing model triangulates at least two independent methods before accepting a patient count. For the GCC, that means a nephrology network capacity survey against biopsy-rate diagnostic-yield evidence, since no GCC state maintains a national registry specific to IgA nephropathy. This is explicitly a sizing model of a static patient count, distinct from a forecasting or patient-flow model of dynamic uptake.
GCC IgA nephropathy sizing sources: the GCC nephrology network capacity survey 2022, the KDIGO 2021 IgAN guideline, the SFDA drug registration database query 2024, and the Gulf renal registry 2022.
- GCC prevalence estimate and biopsy rate verified against the GCC nephrology network capacity survey 2022
- Biopsy-rate benchmarking against Japan and Germany verified against KDIGO 2021 IgAN guideline standards
- Zero-registered-novel-agent status confirmed against the SFDA drug registration database query 2024
- A hard biopsy-confirmed patient count is a genuine data gap for the GCC; no figure was invented in its place, consistent with the AXLRx GCC IgA Nephropathy Patient Flow Model
Frequently asked questions
Commission this model
AXLRx delivers GCC IgA nephropathy market sizing models built for forecasting and strategy teams sizing the treatment-eligible opportunity ahead of SFDA registration. Custom model in 72 hours.
Specify your indication, GCC market, and cohort definition.
AXLRx analyst confirms triangulation methods and comparator set before building.
Research-verified sizing model in 72 hours with optional analyst readout.